Eltrombopag for Post Transplant Thrombocytopenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01000051|
Recruitment Status : Completed
First Posted : October 22, 2009
Results First Posted : July 30, 2019
Last Update Posted : July 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Thrombocytopenia||Drug: Eltrombopag Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||64 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Eltrombopag for Post Transplant Thrombocytopenia|
|Actual Study Start Date :||February 17, 2010|
|Actual Primary Completion Date :||April 4, 2018|
|Actual Study Completion Date :||April 4, 2018|
Starting dose 50 mg/day orally for 8 weeks
Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
Other Name: Promacta
Placebo Comparator: Placebo
Once a day orally for 8 weeks
Once a day, orally for 8 weeks.
- Comparing the Efficacy of Eltrombopaq and Placebo [ Time Frame: Baseline to Day 57 ]Comparison of the efficacy of eltrombopag and placebo in patients with thrombocytopenia post hematopoietic cell transplantation (HCT).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01000051
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Study Chair:||Uday Popat, MD||M.D. Anderson Cancer Center|